Company - Bioclarma

Welcome in Bioclarma

Innovation in Molecular Diagnostics

A decade of innovation in service of health.

For over a decade, Bioclarma has established itself as a reference point in the production of in vitro medical diagnostic devices, providing reliable and cutting-edge solutions for hospital diagnostic laboratories in Italy and around the world.

Our company is committed to providing high-quality diagnostic tools to address the challenges of diagnosis and monitoring in onco-hematological diseases.

Advanced tools
for the detection of Molecular Markers
in Leukemias

Our kits are designed for the diagnosis and monitoring of leukemias caused by the BCR/ABL fusion gene resulting from the t(9;22) translocation (Philadelphia Chromosome) and are capable of detecting and quantifying the following variants:
major P210, minor P190, micro P230, and the rare b3a3/b2a3, e1a3, nano (e6a2/e6a3).

Additionally, we offer solutions for other relevant genetic translocations such as:
PML/RARa t(15;17), AML1-ETO t(8;21) and CBFB/MYH11 t(16;16).

Oltre ai kit per le traslocazioni genetiche, disponiamo di una
linea di prodotti per la rilevazione dei difetti dei fattori della coagulazione.

Additionally, Bioclarma offers a product line for the diagnosis of hereditary thrombophilia associated with polymorphisms in the Factor II (Prothrombin), Factor V, and Methylenetetrahydrofolate Reductase (MTHFR) genes, utilizing a direct method that does not require DNA purification.

Analysis and on-demand services.

We offer a wide range of on-demand services, including:

Luminex Analysis
Molecular Biology Analysis
Proteomic Analysis
Immuno-Assay

To address the requirements of research laboratories dedicated to the discovery and development of cutting-edge medical therapies.

Join us in our commitment to excellence in medical diagnostics.

Bioclarma provide reliable and customized solutions to support your mission of delivering high-quality care and improving patient health worldwide.